The DOI matches its Crossref record.
Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Abstract
The heart is an aerobic organ, and most of the energy required for the contraction and maintenance of ion gradients comes from oxidative phosphorylation. Oxidative stress caused by free radicals plays a crucial role in the pathophysiology associated with atherosclerosis, neoplasia and neurodegenerative diseases. Therefore, a great deal of attention has focused on the naturally occurring antioxidant phytochemicals as potential therapy for cardiovascular diseases. One of the most recognized and widely studied compounds is resveratrol, a member of a family of polyphenols called viniferins. Although resveratrol was first isolated in 1940 from the roots of white hellebore (Veratrum grandiflorum), the importance of resveratrol was recognized only after the widely publicized historic "French Paradox" associated with drinking of red wine. Both epidemiological and experimental studies have revealed that drinking wine, particularly red wine, in moderation protects cardiovascular health; however, the experimental basis for such an action is not fully understood. A growing body of evidence supports the role of resveratrol as evidence based cardiovascular medicine. Resveratrol protects the cardiovascular system by multidimensional way. The most important point about resveratrol is that at a very low concentration, it inhibits apoptotic cell death, thereby providing protection from various diseases including myocardial ischemic reperfusion injury, atherosclerosis and ventricular arrhythmias. Both in acute and in chronic models, resveratrol-mediated cardioprotection is achieved through the preconditioning effect (the state-of-the-art technique of cardioprotection), rather than direct effect as found in conventional medicine. The same resveratrol when used in higher doses, it facilitates apoptotic cell death, and behaves as a chemo-preventive alternative. Resveratrol likely fulfills the definition of a pharmacological preconditioning compound and gives hope for the therapeutic promise of alternative medicine. The purpose of this review is to provide evidence in favor of resveratrol to be used as a preventive medicine and related patents for the maintenance of healthy heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Administration of resveratrol: What formulation solutions to bioavailability limitations?
Amri, A., Chaumeil, J. C., Sfar, S., & Charrueau, C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.083 · Cited by 620
Biological activity of piceatannol: Leaving the shadow of resveratrol
Piotrowska, H., Kucinska, M., & Murias, M. (2012) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.11.001 · Cited by 476
Teka, T., Zhang, L., Ge, X., Li, Y., Han, L., & Yan, X. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113128 · Cited by 216
Lysine deacetylation in ischaemic preconditioning: the role of SIRT1
Nadtochiy, S. M., Redman, E., Rahman, I., & Brookes, P. S. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq287 · Cited by 130
Metadata
- Authors
- Samarjit Das, B. S. P., & Dipak K. Das, B. S. P.
- Venue
- Recent Patents on Cardiovascular Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-06-01
- Volume
- 2
- Issue
- 2
- Pages
- 133-138
- ISSN
- 1574-8901 (ISSN-L)
- OpenAlex
- W1975176641
- Cited by
- 158
- References
- 0
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resveratrol: A Therapeutic Promise for Cardiovascular Diseases. https://app.cochat.ai/papers/10.2174/157489007780832560
- The paper
- Samarjit Das, B. S. P., & Dipak K. Das, B. S. P. (2007). Resveratrol: A Therapeutic Promise for Cardiovascular Diseases. Recent Patents on Cardiovascular Drug Discovery. https://doi.org/10.2174/157489007780832560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.